Data compiled by Redley Lamar · ChainSifter Intelligence
5Suppliers
8Customers
2Debt Items
20Related Chains
Source-Backed Evidence Depth
Hepion Pharmaceuticals, Inc. (HEPA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
16Total relationships
3Distinct source URLs
5High confidence
0.734Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Hepion Pharmaceuticals, Inc. Suppliers
Ticker
Name
Confidence
Evidence
CIRNA-DIAGNOSTICS-LLC
CIRNA-DIAGNOSTICS-LLC
92%
The Company licensed certain liver disease diagnostic assets from Cirna.
NEW-DAY
NEW-DAY
90%
Pursuant to the License Agreement, the Company paid $ 525,000 in cash to New Day along with $ 270,629 in common stock of the Company.
Reciprocal relationship from CTRVP graph: and 2022 are related to our foreign operations. Contingencies In the normal course of business, we are subject to loss contingencies, such as legal proceedin…
Reciprocal relationship from OKYO graph: oreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign exchange ga…
Reciprocal relationship from TLSA graph: Reciprocal relationship from HEPA graph: Reciprocal relationship from TLSA graph: or of Hepion Pharmaceuticals, Inc. from December 2013 until June 2025, Actav…
Reciprocal relationship from VKTX graph: Reciprocal relationship from HEPA graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from HEPA graph: Reciprocal relationship from VKTX g…
CIRNA-DIAGNOSTICS-LLC
CIRNA-DIAGNOSTICS-LLC
62%
. Overview Hepion Pharmaceuticals, Inc. (we, our, or us) is a medical diagnostic company headquartered in Red Bank, New Jersey, that was previously focused on the development of drug therapy for trea…
CONTRAVIR-RESEARCH-INC
CONTRAVIR-RESEARCH-INC
62%
4 The accompanying notes are an integral part of these condensed consolidated financial statements (unaudited). 6 Table of Contents HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES Notes to Condensed Co…
HEPION-RESEARCH-CORP
HEPION-RESEARCH-CORP
62%
4 The accompanying notes are an integral part of these condensed consolidated financial statements (unaudited). 6 Table of Contents HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES Notes to Condensed Co…
NEW-DAY-DIAGNOSTICS-LLC
NEW-DAY-DIAGNOSTICS-LLC
62%
reement, the Merger Agreement was terminated. On May 9, 2025, Hepion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into a license agreement (“License Agreement”) with New Day…
OVERVIEW-HEPION-PHARMACEUTICALS-INC
OVERVIEW-HEPION-PHARMACEUTICALS-INC
62%
. Overview Hepion Pharmaceuticals, Inc. (we, our, or us) is a medical diagnostic company headquartered in Red Bank, New Jersey, that was previously focused on the development of drug therapy for trea…
PANETTA-PARTNERS-LIMITED
PANETTA-PARTNERS-LIMITED
62%
reement, the Merger Agreement was terminated. On May 9, 2025, Hepion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into a license agreement (“License Agreement”) with New Day…
PEARL-MERGER-SUB-INC
PEARL-MERGER-SUB-INC
62%
dit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the …
Hepion Pharmaceuticals, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
HEPA-DEBT-10002
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
HEPA-DEBT-10001
Warrants outstanding: 553846
90%
xbrl warrant detail from xbrl 2025-12-31.
Hepion Pharmaceuticals, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Hepion Pharmaceuticals, Inc..
Hepion Pharmaceuticals, Inc. Ownership
Holder
Name
Confidence
Evidence
HEPA-OWNER-BARCLAYS-PLC
BARCLAYS PLC
90%
13F overlay lists BARCLAYS PLC as top holder; 1 tracked holders.
Hepion Pharmaceuticals, Inc. Extended Supply Chain Network
